Guidance published in 2026 by the International Society on Thrombosis and Haemostasis (ISTH) was developed to summarize the limited available evidence and provide consensus recommendations for the monitoring, initiation, and dose adjustment of therapeutic unfractionated heparin. The guidance does not identify an evidence-based maximum patient-weight cap for heparin infusion dosing and specifically defers recommendations for special populations, including patients with obesity, to subsequent guidance. It recommends using a weight-based nomogram but concludes that available evidence is insufficient to favor one nomogram or dosing cap over another. Although a retrospective study in patients with mechanical mitral valves used maximum initial infusion rates of 1,000 units/hour for a low-intensity regimen and 1,800 units/hour for a high-intensity regimen, the study was not powered to detect differences in thrombotic or bleeding outcomes; therefore, these limits should not be interpreted as broadly supported weight caps. [1]
Furthermore, the guidance describes different dosing intensities and targets according to indication, including acute coronary syndrome (ACS) and mechanical-valve bridging, but it does not establish separate maximum dosing weights for different indications. Regarding subtherapeutic anticoagulation, the paper does not provide evidence supporting a routine no-bolus protocol. Instead, it suggests a weight-based nomogram that includes an initial bolus and subsequent dose adjustments; the cited randomized trial found that initial and repeated boluses as needed improved attainment of therapeutic anticoagulation within 24 hours and were associated with fewer recurrent venous thromboembolic events than standard care. However, because published nomograms differ in their use of boluses and none have been validated using clinical events as the primary outcome, the guidance cannot recommend one specific bolus or no-bolus adjustment strategy over another. [1]
A 2016 guidance document notes that current heparin dosing recommendations do not specify which body weight should be used for weight-based dosing. The authors also note that the original Raschke nomogram was developed using actual body weight, although only 9 of 115 patients (<8%) weighed more than 100 kg (range 101–131 kg). Because available evidence is limited by low-quality studies, heterogeneous dosing strategies, and small sample sizes, the guidance suggests using total body weight when a weight-based dosing strategy is selected, while either total body weight or adjusted body weight may be used in obese or morbidly obese patients with close monitoring of anticoagulation parameters. The guidance cautions that empiric dose caps may increase the risk of initial under-anticoagulation in obese patients and recommends individualized dosing if dose caps are used. Although no increased risk of major bleeding has been reported with total body weight-based dosing in morbidly obese patients, available studies have not included patients weighing >270 kg. [2]
A 2022 literature review of PubMed studies addressed three questions on UFH bolus use: the function and therapeutic-range goals of an initial bolus, and the risks of subtherapeutic and supratherapeutic activated partial thromboplastin time (aPTT). It was determined that patients already anticoagulated should not receive an initial UFH bolus, while non-anticoagulated patients benefit from a bolus based on indication (e.g., 80 units/kg then 18 units/kg/hr for VTE), reaching therapeutic aPTT roughly 60 minutes sooner than without a bolus (9.6±7.3 vs 14.5±10.8 hours). However, neither group showed a significantly greater likelihood of achieving or maintaining therapeutic aPTT range overall. Subtherapeutic aPTT was linked to 20–25% VTE recurrence, while each 10-second aPTT increase above the prespecified goal range raised major bleeding risk by roughly 7%. As a non-systematic, single-institution literature synthesis without original patient-level data or a defined selection methodology, its conclusions are best viewed as a practical clinical summary rather than high-grade evidence. Additionally, this study was available only as a published conference abstract; as such, the full results were not able to be independently verified. [3]